U.S. Pharmaceuticals & Biotech Buy the Dip

BridgeBio Pharma

Market Cap: US$16.2b

A biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.

Arrowhead Pharmaceuticals

Market Cap: US$10.1b

Develops medicines for the treatment of intractable diseases in the United States.

ImmunityBio

Market Cap: US$8.1b

A biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.

Mirum Pharmaceuticals

Market Cap: US$7.4b

A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.

PTC Therapeutics

Market Cap: US$6.5b

A biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.

Definium Therapeutics

Market Cap: US$6.1b

A clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders.

Ligand Pharmaceuticals

Market Cap: US$5.9b

A biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.

Celcuity

Market Cap: US$4.5b

A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.

Tango Therapeutics

Market Cap: US$4.4b

A precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.

NewAmsterdam Pharma

Market Cap: US$3.7b

A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.

Structure Therapeutics

Market Cap: US$3.5b

A clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.

Arcus Biosciences

Market Cap: US$3.5b

A clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.

Celldex Therapeutics

Market Cap: US$3.0b

A biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.

uniQure

Market Cap: US$2.8b

Develops treatments for patients suffering from rare and other devastating diseases in the United States.

Immunome

Market Cap: US$2.6b

A biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.

Tarsus Pharmaceuticals

Market Cap: US$2.5b

A commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.

Syndax Pharmaceuticals

Market Cap: US$2.1b

A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.

Taysha Gene Therapies

Market Cap: US$2.0b

A clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.

Stoke Therapeutics

Market Cap: US$1.9b

Engages in the development of treatments for severe genetic diseases by upregulating protein expression.

Precigen

Market Cap: US$1.8b

A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.

COMPASS Pathways

Market Cap: US$1.8b

Operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.

Zymeworks

Market Cap: US$1.8b

A biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases.

AnaptysBio

Market Cap: US$1.7b

A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.

Capricor Therapeutics

Market Cap: US$1.2b

A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.

MeiraGTx Holdings

Market Cap: US$1.2b

A clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases.

Olema Pharmaceuticals

Market Cap: US$1.0b

A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.

Solid Biosciences

Market Cap: US$947.1m

Develops therapies for neuromuscular and cardiac diseases in the United States.

Phathom Pharmaceuticals

Market Cap: US$877.7m

A biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States.

Design Therapeutics

Market Cap: US$844.4m

A clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.

Neurogene

Market Cap: US$786.1m

A clinical stage biotechnology company, develops genetic medicines for rare neurological diseases.

Omeros

Market Cap: US$750.5m

A clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.

Immix Biopharma

Market Cap: US$749.6m

A clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.

Ironwood Pharmaceuticals

Market Cap: US$658.5m

A biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.

Allogene Therapeutics

Market Cap: US$655.8m

A clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

Tectonic Therapeutic

Market Cap: US$613.2m

A biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs).

4D Molecular Therapeutics

Market Cap: US$610.6m

A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.